Education
About Us
Working with TipRanks
Follow Us
Sangamo Biosciences (SGMO)
NASDAQ:SGMO
SGMO Stock Chart & Stats
$0.45
-$0.13(-9.49%)
At close: 4:00 PM EST
$0.45
-$0.13(-9.49%)
Day’s Range― - ―
52-Week Range$0.38 - $2.73
Previous CloseN/A
Volume2.84M
Average Volume (3M)7.65M
Market Cap
$150.21M
Enterprise Value$199.79M
Total Cash (Recent Filing)$30.53M
Total Debt (Recent Filing)$25.42M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Feb 25, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding336,494,480
10 Day Avg. Volume4,237,466
30 Day Avg. Volume7,646,780
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)9.04
Price to Sales (P/S)3.56
P/FCF Ratio-3.05
Enterprise Value/Market Cap1.33
Enterprise Value/Revenue6.08
Enterprise Value/Gross Profit6.08
Enterprise Value/Ebitda-1.94
Forecast
1Y Price Target
$4.33Price Target Upside862.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$59.32M
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessFull data from the registrational Phase 1/2 STAAR trial further validated isaralgagene civaparvovec as a one-time, durable gene therapy for Fabry disease.
Regulatory MilestonesThe FDA’s acceptance of Sangamo’s request for a rolling Biologics License Application submission for ST-920 in Fabry disease confirms regulatory momentum toward full BLA filing and strengthens the Accelerated Approval pathway.
Strategic PartnershipsSangamo has high-quality, value-generating partnerships and a lean operating model, positioning it well to deliver on a differentiated neurology pipeline.
Bears Say
Shareholder Dilution RiskA gross capital raise of $150 million in 2026 could dilute existing shareholders.
Sangamo Biosciences News
SGMO FAQ
What was Sangamo Biosciences’s price range in the past 12 months?
Sangamo Biosciences lowest stock price was $0.38 and its highest was $2.73 in the past 12 months.
What is Sangamo Biosciences’s market cap?
Sangamo Biosciences’s market cap is $150.21M.
When is Sangamo Biosciences’s upcoming earnings report date?
Sangamo Biosciences’s upcoming earnings report date is Feb 25, 2026 which is in 66 days.
How were Sangamo Biosciences’s earnings last quarter?
Sangamo Biosciences released its earnings results on Nov 06, 2025. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of $0 by -$0.11.
Is Sangamo Biosciences overvalued?
According to Wall Street analysts Sangamo Biosciences’s price is currently Undervalued.
Does Sangamo Biosciences pay dividends?
Sangamo Biosciences does not currently pay dividends.
What is Sangamo Biosciences’s EPS estimate?
Sangamo Biosciences’s EPS estimate is -0.01.
How many shares outstanding does Sangamo Biosciences have?
Sangamo Biosciences has 336,494,480 shares outstanding.
What happened to Sangamo Biosciences’s price movement after its last earnings report?
Sangamo Biosciences reported an EPS of -$0.11 in its last earnings report, missing expectations of $0. Following the earnings report the stock price went down -16.364%.
Which hedge fund is a major shareholder of Sangamo Biosciences?
Currently, no hedge funds are holding shares in SGMO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sangamo Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.33 (862.22% Upside)
$4.33 (862.22% Upside)
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.70%
12-Months-Change
Fundamentals
Return on Equity
-480.02%
Trailing 12-Months
Asset Growth
-20.33%
Trailing 12-Months
Company Description
Sangamo Biosciences
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
SGMO Company Deck
SGMO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical advancements in Fabry disease and neurology programs, endorsement from the FDA, and an extended cash runway. However, there are ongoing challenges in securing long-term funding and potential regulatory uncertainties. Overall, the highlights outweigh the lowlights, indicating a positive outlook.View all SGMO earnings summariesSGMO Stock 12 Month Forecast
Average Price Target
$4.33
▲(862.22% Upside)
Technical Analysis
Applied Therapeutics
―
Cabaletta Bio
―
Black Diamond Therapeutics
―
Elicio Therapeutics
―
Caribou Biosciences
―
Ownership Overview
1.60% Insiders
5.56% Mutual Funds
2.17% Other Institutional Investors
87.07% Public Companies and Individual Investors